| Mr Daniel Hering, PHYSICIANS ASSITANT | |
|
303 Marion Ave, Mccomb, MS 39648-2707 | |
| (601) 249-2701 | |
| (601) 249-2226 |
| Full Name | Mr Daniel Hering |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 20 Years |
| Location | 303 Marion Ave, Mccomb, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891743183 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AM0700X | Physician Assistant - Medical | PA072 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lampton Medical Asscoiates, Pa | 5294059051 | 2 |
News Archive
Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, today announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes.
The Brain Research Foundation (BRF) today announced it will fund research that aims to improve pediatricians' ability to evaluate and manage sports-related concussive injuries among young children, and guide future research regarding the diagnosis, treatment and long term effects of these events.
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Daniel Hering, PHYSICIANS ASSITANT 303 Marion Ave, Mccomb, MS 39648-2707 Ph: (601) 249-2701 | Mr Daniel Hering, PHYSICIANS ASSITANT 303 Marion Ave, Mccomb, MS 39648-2707 Ph: (601) 249-2701 |
News Archive
Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases, today announced a study of obese primates treated with RM-493 showing a reversal of obesity and insulin resistance, and improvement in both heart rate and blood pressure. RM-493 is a novel peptide agonist targeting the melanocortin 4 receptor (MC4R) that is a clinical candidate for the treatment of obesity and diabetes.
The Brain Research Foundation (BRF) today announced it will fund research that aims to improve pediatricians' ability to evaluate and manage sports-related concussive injuries among young children, and guide future research regarding the diagnosis, treatment and long term effects of these events.
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on this targeting ability, using a modified anti-EGFR antibody to delivery nanoparticles into tumor cells.
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced that the U.S. Food and Drug Administration (FDA) has approved the company's application for accelerated approval of its seasonal flu vaccine, Afluria® (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older.
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
› Verified 7 days ago
Heather Huguley, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1701 White St, Mccomb, MS 39648 Phone: 601-249-4218 Fax: 601-249-4234 |